Perceived Health Status among Patients with Norovirus and Acute Gastroenteritis
Author(s)
Holly C. Groom, MPH1, Matthew Slaughter, MS1, Emma Viscidi, PhD2, John Dickerson, PhD1, Maureen Rosetti, MS1, Judy Donald, MS1, Carly Crocker, BS3, Wen-Hsing Wu, MS3, Michelle Blake, BSc, MSc, PhD3, Philip Buck, MPH, PhD2, Katherine Carlson, PhD3, Mark Schmidt, PhD1;
1Kaiser Permanente Northwest, Center for Health Research, Portland, OR, USA, 2Moderna, Inc, Cambridge, MA, USA, 3Moderna, Inc., Cambridge, MA, USA
1Kaiser Permanente Northwest, Center for Health Research, Portland, OR, USA, 2Moderna, Inc, Cambridge, MA, USA, 3Moderna, Inc., Cambridge, MA, USA
Presentation Documents
OBJECTIVES: To assess the impact of norovirus on health-related quality of life (HRQoL) among individuals with medically-attended acute gastroenteritis (MA-AGE) aged 5 years and older.
METHODS: Study of Acute Gastroenteritis (SAGE) was a prospective study conducted from November 2023-September 2024 at Kaiser Permanente Northwest, an integrated healthcare system in Oregon and Washington, USA. Participants presenting with MA-AGE completed an enrollment survey and provided a stool specimen for norovirus testing. The survey included a validated HRQoL instrument to assess participant perceived health status, the 5-dimension EuroQoL (EQ-5D), which includes a visual analog scale (VAS) to rate health on a scale from 0 (worst health) to 100 (best possible health). Participants completed the EQ-5D considering how they felt before and on their worst day of AGE illness. Decrements in VAS were compared between timepoints by norovirus positivity, and stratified by age group, using Wilcoxon rank-sum tests.
RESULTS: Our analysis included 772 adults; 119 (15%) norovirus-positive and 653 negative, and 34 children, 15 (44%) norovirus-positive and 19 negative. The median decrements in VAS from pre-illness to worst day were significantly greater among norovirus-positive vs. norovirus-negative patients across all age groups. Legal guardians of norovirus-positive children reported a median decrement of 70, compared to 44 among norovirus-negative children (p<0.01). Among adults, the median decrement in VAS among norovirus-positives vs. norovirus-negatives was 50 vs. 35 (p<0.01) for adults 18-49; 51.5 vs. 35 (p<0.01) for adults 50-64; 55 vs. 30.5 (p<.01) for adults 65-74; and 52.5 vs. 20.5 (p<0.01) for adults 75+.
CONCLUSIONS: In a real-world study of MA-AGE patients in the US, all patients reported declines in health status from before illness to their worst day of illness. However, patients with confirmed norovirus experienced significantly greater reductions in their perceived health status than those with norovirus-negative AGE, highlighting the significant impact of norovirus on HRQoL across all age groups.
METHODS: Study of Acute Gastroenteritis (SAGE) was a prospective study conducted from November 2023-September 2024 at Kaiser Permanente Northwest, an integrated healthcare system in Oregon and Washington, USA. Participants presenting with MA-AGE completed an enrollment survey and provided a stool specimen for norovirus testing. The survey included a validated HRQoL instrument to assess participant perceived health status, the 5-dimension EuroQoL (EQ-5D), which includes a visual analog scale (VAS) to rate health on a scale from 0 (worst health) to 100 (best possible health). Participants completed the EQ-5D considering how they felt before and on their worst day of AGE illness. Decrements in VAS were compared between timepoints by norovirus positivity, and stratified by age group, using Wilcoxon rank-sum tests.
RESULTS: Our analysis included 772 adults; 119 (15%) norovirus-positive and 653 negative, and 34 children, 15 (44%) norovirus-positive and 19 negative. The median decrements in VAS from pre-illness to worst day were significantly greater among norovirus-positive vs. norovirus-negative patients across all age groups. Legal guardians of norovirus-positive children reported a median decrement of 70, compared to 44 among norovirus-negative children (p<0.01). Among adults, the median decrement in VAS among norovirus-positives vs. norovirus-negatives was 50 vs. 35 (p<0.01) for adults 18-49; 51.5 vs. 35 (p<0.01) for adults 50-64; 55 vs. 30.5 (p<.01) for adults 65-74; and 52.5 vs. 20.5 (p<0.01) for adults 75+.
CONCLUSIONS: In a real-world study of MA-AGE patients in the US, all patients reported declines in health status from before illness to their worst day of illness. However, patients with confirmed norovirus experienced significantly greater reductions in their perceived health status than those with norovirus-negative AGE, highlighting the significant impact of norovirus on HRQoL across all age groups.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
PCR68
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
SDC: Gastrointestinal Disorders, SDC: Infectious Disease (non-vaccine)